
|Videos|October 7, 2021
Dr. Nickel discusses the safety of novel recurrent UTI vaccine
Author(s)Urology Times staff
“It is a vaccine that is self-administered by the patient sublingual over 3 months, and that is why it appears to be so safe,” says J. Curtis Nickel, MD.
Advertisement
In this video, J. Curtis Nickel, MD, discusses the safety of the MV140 vaccine, used to treat patients with recurrent urinary tract infections. Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
4
Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD
5






